Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) witnessed a sharp surge in its share price on Tuesday after confirming a definitive acquisition deal with SERB Pharmaceuticals. YMAB stock jumped 103.34%, closing at $8.52.
SERB to Acquire Y-mAbs and Lead Oncology Asset
The agreement states that SERB would buy Y-mAbs for $8.60 per share, which is 105% more than the closing price on August 4, 2025, in an all-cash deal of around $412 million.
The acquisition of Y-mAbs, including its main commercial cancer medicine DANYELZA (naxitamab-gqgk), will be by SERB Pharmaceuticals, a multinational specialty pharmaceutical firm that focuses on rare illnesses and medical crises.
An all-cash tender offer for all outstanding Y-mAbs common shares will be used to complete the transaction. After Y-mAbs’ Board of Directors conducted a thorough strategic assessment with the goal of optimizing shareholder value, the deal was unanimously accepted.
The Process of Strategic Review
The Y-mAbs Board hired outside counsel and looked at a number of possibilities, including as possible purchasers for the business overall, sales of particular assets, and chances to raise more money to develop its pipeline. The Board concluded that SERB’s offer offered the most alluring, immediate, and assured value for shareholders after assessing many options.
The Growth and Strategic Fit of SERB
After SERB expanded into the U.S. market five years ago, this acquisition fits with the company’s overall growth strategy. By enhancing SERB’s rare oncology portfolio, DANYELZA allows the business to expand the drug’s commercial reach by using its worldwide presence and regulatory experience.
The FDA-approved product and well-established commercial base of Y-mAbs will blend together well with SERB’s specialized expertise, strengthening their mutual dedication to enhancing patient outcomes globally.
Closing Schedule and Prospects
It is projected that the deal will conclude by the fourth quarter of 2025, pending closing requirements and standard regulatory clearances. Both businesses expressed hope that their combined resources and experience will improve DANYELZA’s worldwide accessibility and provide patients, families, and stakeholders with significant benefits.
